Physician profile
David Scott Sharp
NPI 1275720344
$5,691.21
in general payments reported to CMS, 2019-2025
25 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.92 · 2021: $2,100 · 2022: $995 · 2023: $825 · 2024: $1,067 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,666.45 | 2021-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $1,162.40 | 2021-2025 | Lithovue, Moses 550 Dfl, Spaceoar Vue System - 10ml |
| Intuitive Surgical, INC. | $1,129.93 | 2021-2022 | |
| Urogen Pharma, INC. | $243.20 | 2022-2025 | Jelmyto |
| Accord Healthcare, INC. | $210.24 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.23 | 2022-2023 | |
| Astellas Pharma US INC | $166.97 | 2021-2024 | Myrbetriq, Veozah |
| Endo USA, INC. | $147.45 | 2024-2025 | Xiaflex, Aveed |
| 180 Medical, INC. | $129.21 | 2021-2025 | Gentlecath |
| Dornier Medtech America, INC | $102.07 | 2021 | |
| Endo Pharmaceuticals INC. | $93.47 | 2021-2023 | Xiaflex, Aveed |
| Olympus America INC. | $86.09 | 2024-2025 | Itind System |
| Antares Pharma, INC. | $47.42 | 2024 | Xyosted |
| Janssen Biotech, INC. | $44.43 | 2021-2025 | Erleada |
| Ethicon US, LLC | $38.97 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $37.03 | 2025 | Gemtesa |
| Urovant Sciences INC | $30.77 | 2022 | |
| Dendreon Pharmaceuticals LLC | $29.57 | 2023 | Provenge |
| Convatec INC. | $28.94 | 2023 | |
| Ambu INC. | $23.63 | 2022 | |
| Covidien Lp | $21.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.82 | 2025 | |
| Myriad Genetic Laboratories, INC. | $19.83 | 2024 | Myrisk |
| Abbvie INC. | $19.27 | 2023 | Lupron Depot |
| E.R. Squibb & Sons, L.L.C. | $17.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.